The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

Alessi, 1998, Mechanism of activation and function of protein kinase B, Curr. Opin. Genet. Dev., 8, 55, 10.1016/S0959-437X(98)80062-2 Baselga, 2000, Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin, J. Clin. Oncol., 18, 904, 10.1200/JCO.2000.18.4.904 Baselga, 2002, Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types, J. Clin. Oncol., 20, 4292, 10.1200/JCO.2002.03.100 Basso, 2002, Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2, Oncogene, 21, 1159, 10.1038/sj.onc.1205184 Bedogni, 2004, Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice, Cancer Res., 64, 2552, 10.1158/0008-5472.CAN-03-3327 Bianco, 2003, Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors, Oncogene, 22, 2812, 10.1038/sj.onc.1206388 Bonni, 1999, Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms, Science, 286, 1358, 10.1126/science.286.5443.1358 Chakravarti, 2002, The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner, Cancer Res., 62, 4307 Datta, 1997, Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery, Cell, 91, 231, 10.1016/S0092-8674(00)80405-5 Datta, 2000, 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation, Mol. Cell, 6, 41, 10.1016/S1097-2765(00)00006-X De Luca, 1999, EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells, Int. J. Cancer, 80, 589, 10.1002/(SICI)1097-0215(19990209)80:4<589::AID-IJC17>3.0.CO;2-D Ekstrand, 1994, Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification, Oncogene, 9, 2313 Fang, 1999, Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway, Oncogene, 18, 6635, 10.1038/sj.onc.1203076 Fernando, 2004, Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt, Mol. Biol. Cell, 15, 3266, 10.1091/mbc.E03-11-0823 Frederick, 2000, Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas, Cancer Res., 60, 1383 Garcia-Echeverria, 2004, In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase, Cancer Cell, 5, 231, 10.1016/S1535-6108(04)00051-0 Gilmore, 2002, Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor, J. Biol. Chem., 277, 27643, 10.1074/jbc.M108863200 Harari, 2004, Epidermal growth factor receptor inhibition strategies in oncology, Endocr. Relat. Cancer, 11, 689, 10.1677/erc.1.00600 Hayakawa, 2000, Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin, Cancer Res., 60, 5988 Huang, 1997, The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling, J. Biol. Chem., 272, 2927, 10.1074/jbc.272.5.2927 Lee, 2003, Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent pathways cooperate to maintain lung cancer cell survival, J. Biol. Chem., 278, 23630, 10.1074/jbc.M300997200 Li, 1997, PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer, Science, 275, 1943, 10.1126/science.275.5308.1943 Markowitz, 1990, Growth stimulation by coexpression of transforming growth factor-α and epidermal growth factor-receptor in normal and adenomatous human colon epithelium, J. Clin. Invest., 86, 356, 10.1172/JCI114709 Markowitz, 1994, A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progresses to tumorigenicity and transforming growth factor-β independence without inactivating the p53 tumor suppressor gene, J. Clin. Invest., 93, 1005, 10.1172/JCI117048 Mendelsohn, 2000, The EGF receptor family as targets for cancer therapy, Oncogene, 19, 6550, 10.1038/sj.onc.1204082 Moasser, 2001, The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells, Cancer Res., 61, 7184 Moscatello, 1998, Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor, J. Biol. Chem., 273, 200, 10.1074/jbc.273.1.200 Nicholson, 1995, Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis, Nature, 376, 37, 10.1038/376037a0 Nusse, 1990, Flow cytometric analysis of G1- and G2/M-phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurements, Cytometry, 11, 813, 10.1002/cyto.990110707 Olayioye, 2000, The ErbB signaling network: receptor heterodimerization in development and cancer, EMBO J., 19, 3159, 10.1093/emboj/19.13.3159 Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314 Pao, 2004, EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc. Natl. Acad. Sci. USA, 101, 13306, 10.1073/pnas.0405220101 Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Med., 2, e17, 10.1371/journal.pmed.0020017 Ram, 2000, Heregulin-β is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells, J. Cell. Physiol., 183, 301, 10.1002/(SICI)1097-4652(200006)183:3<301::AID-JCP2>3.0.CO;2-W Ramaswamy, 1999, Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway, Proc. Natl. Acad. Sci. USA, 96, 2110, 10.1073/pnas.96.5.2110 Rojas, 1996, Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor, J. Biol. Chem., 271, 27456, 10.1074/jbc.271.44.27456 Salomon, 1995, Epidermal growth factor-related peptides and their receptors in human malignancies, Crit. Rev. Oncol. Hematol., 19, 183, 10.1016/1040-8428(94)00144-I Samuels, 2004, High frequency of mutations of the PIK3CA gene in human cancers, Science, 304, 554, 10.1126/science.1096502 Scheid, 1999, Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase, J. Biol. Chem., 274, 31108, 10.1074/jbc.274.43.31108 Sebolt-Leopold, 2004, MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors, Curr. Pharm. Des., 10, 1907, 10.2174/1381612043384439 She, 2003, Inhibition of cell transformation by resveratrol and its derivatives: differential effects and mechanisms involved, Oncogene, 22, 2143, 10.1038/sj.onc.1206370 She, 2003, Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling, Clin. Cancer Res., 9, 4340 Shin, 2001, Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer, Clin. Cancer Res., 7, 1204 Soltoff, 1994, ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor, Mol. Cell. Biol., 14, 3550, 10.1128/MCB.14.6.3550 Srethapakdi, 2000, Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest, Cancer Res., 60, 3940 Thomas, 2001, Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells, Acta Neuropathol. (Berl.), 101, 605, 10.1007/s004010000332 Tsao, 2004, Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma, J. Invest. Dermatol., 122, 337, 10.1046/j.0022-202X.2004.22243.x Uzgare, 2004, Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells, Cancer Res., 64, 6190, 10.1158/0008-5472.CAN-04-0968 Wan, 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell, 116, 855, 10.1016/S0092-8674(04)00215-6 Woodburn, 1999, The epidermal growth factor receptor and its inhibition in cancer therapy, Pharmacol. Ther., 82, 241, 10.1016/S0163-7258(98)00045-X Yang, 1995, Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death, Cell, 80, 285, 10.1016/0092-8674(95)90411-5 Yarden, 2001, Untangling the ErbB signalling network, Nat. Rev. Mol. Cell Biol., 2, 127, 10.1038/35052073 Zha, 1996, Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L), Cell, 87, 619, 10.1016/S0092-8674(00)81382-3